Test Price
2,800 AED✅ Home Collection Available
DOCK7 Gene Early Infantile Epileptic Encephalopathy Type 23 (EIEE23) Genetic Test
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing (ISO 9001:2015 Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation and next-step counselling.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This test sequences the entire coding region of the DOCK7 gene using Next‑Generation Sequencing (NGS) to detect pathogenic variants causing Early Infantile Epileptic Encephalopathy Type 23 (EIEE23), a severe neurological condition with intractable infantile‑onset seizures. The comprehensive analysis includes copy number variant (CNV) detection for deletions or duplications.
| Feature | Our NGS Test (EIEE23) | Alternative Single‑Gene Sequencing |
|---|---|---|
| Precision | Full coding region ± flanking intronic regions (99% coverage >30×) | Often limits to known hotspots; may miss deep intronic or regulatory variants |
| Method | NGS with CNV analysis (deletion/duplication detection) | Sanger sequencing or targeted panel without copy‑number resolution |
| Speed | 3 – 4 Weeks (comprehensive report) | 4 – 6 Weeks (without broader genomic context) |
Physician Insight & Safety Protocols
“Genetic testing for EIEE23 provides critical insights into the underlying cause of infantile seizures. Results must always be interpreted alongside clinical history and EEG findings. This test complements, not replaces, ongoing seizure management. Always adhere to the treatment plan prescribed by your child’s neurologist.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory: Medication and Treatment Guidance
Do not discontinue prescribed antiepileptic drugs or any concurrent therapy without explicit instruction from your treating doctor. Abrupt cessation may worsen seizure control.
Exclusion Criteria & Emergency Red Flags
- Non‑consenting guardian (required by UAE Child Protection Law – Wadeema’s Law).
- Hemodynamically unstable infant or any condition precluding safe venipuncture.
- Seek immediate emergency care if the child experiences: prolonged seizures (>5 minutes), breathing difficulty, loss of consciousness, or any sudden neurological deterioration.
Patient FAQ & Clinical Guidance
1. What is the DOCK7 EIEE23 genetic test and how does it work?
The DOCK7 genetic test uses next‑generation sequencing to analyze all coding exons of the DOCK7 gene, detecting pathogenic variants linked to early infantile epileptic encephalopathy type 23. It requires a small blood sample or dried blood spot, and the laboratory compares your child’s DNA sequence with reference data using advanced bioinformatics to identify disease‑causing mutations.
2. Why is this test recommended for my infant with seizures?
This identifies the precise genetic mutation causing early infantile epileptic encephalopathy type 23, enabling tailored treatment strategies and accurate prognosis for your child. A confirmed DOCK7 mutation can guide medication choice, predict seizure evolution, and provide critical information for family planning.
3. How is the sample collected and how long do results take?
A simple blood draw or a single drop of blood on an FTA card is collected at home by our certified phlebotomist, with results reported within 3 to 4 weeks for comprehensive analysis. Our cold‑chain logistics ensure sample stability from collection to the ISO‑accredited sequencing laboratory.
UAE Regulatory & Data Privacy Adherence
This test is performed under the regulatory framework of the Dubai Health Authority (DHA) and complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted and handled in strict accordance with UAE privacy standards.
Clinical & Logistical Metadata
| Test Name | DOCK7 Gene Early Infantile Epileptic Encephalopathy Type 23 (EIEE23) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3 – 4 Weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA) or dried blood spot (FTA card) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection |
| Methodology Used | Next-Generation Sequencing (NGS) with CNV analysis |
| ICD-10-CM Code | G40.0 |
| LOINC Code | 81247-9 |
| DHA Facility License & Laboratory Address | License Number: 1143 Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians